Objective：To assess the efficacy and tolerability of sibutramine as a weight reduction agent in treatment of overweight patients with type 2 diebetes. Methods： Forty overweight patients （body mass index ≥25 kg/m^2） with type 2 diebetes were randomized into sibutramine treatment group and control group（n= 20）. Both groups received a reduced-calorie diet （deficit of 1 045-2 090 kJ/d from an average daily intake） and continued their original treatment; sibutramine treatment group was also given sibutramine 15 mg once daily for 12 weeks. Before and after sibutramine treatment, body mass index （BMI）, fasting blood glucose （FBG）, fasting serum insulin （FINS）, hemoglobin Alc（ HbAlc ）, and serum lipids were measured in the patients. Homeostasis model assessment （HOMA） was applied to assess the status of insulin resistance （IR）. Results： After treatment, BMI, FBG, H bAlc, TG, FINS and H OMA-IR all decreased （P〈0.01） in sibutramine treatment group. Also in sibutramine treatment group the changes in FBG and TG were correlated with percentage change in body weight （P〈0.01）. Four patients in sibutramine treatment group had a ≥5% weight loss and great decreases in HbAlc and TG. Mild adverse events were no- ticed. Control group had no significant difference in every measurement before and after treatment. Conclusion： Sibutramine can produce significant weight loss in overweight type 2 diabetes patients when used with a reduced-calorie diet; this weight loss is associated with improvement of metabolic control and insulin sensibility. Meanwhile, sibutramine is well tolerated and has less adverse reaction.